Medical/Pharmaceuticals

Ascletis Announces Investment Escalation in R&D of Cancer Lipid Metabolism and Oral Checkpoint Inhibitors

* Proposed Initiation of a Pivotal Phase II Trial of ASC40 in Combination with Bevacizumab in Chinese Patients with First Relapse of High-grade Astrocytoma * In-house discovered oral PD-L1 inhibitors demonstrated favorable anti-tumor activities in the animal model compared to a marketed anti-...

2021-03-30 08:00 4625

Novel Phenomics NASH In Vitro Assay Presented by InSphero AG and PharmaNest Inc at 2021 Society of Toxicology Meeting

Introduction of key technology to accelerate NASH drug discovery by combining 3D disease models and automated AI-based fibrosis quantification PRINCETON, New Jersey, March 30, 2021 /PRNewswire/ -- During the 2021 Society of Toxicology (SOT) Annual Meeting, researchers from Swiss-based InSphero AG...

2021-03-30 05:20 1467

China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020

BEIJING, March 29, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its financial results for the fourth quarter and fiscal year of 2020. Fourt...

2021-03-30 04:30 5152

Amplicore, Inc. Announces Closing of a Successful $4M Seed Funding Round

CINCINNATI, March 30, 2021 /PRNewswire/ -- Amplicore Inc., an early-stage biopharmaceutical company currently developing locally delivered and minimally invasive therapeutic solutions for musculoskeletal diseases, has successfully closed its Series Seed round of funding at$4 million. Investments ...

2021-03-30 02:55 1713

Fosun Pharma Announces 2020 Annual Results

Multiple Innovative Products Launched with Significant Improvement in the Capability of Global Commercialization Net Profit Attributable to Shareholders After Extraordinary G/L Increases 21.65% YOY toRMB2,718 Million SHANGHAI, March 29, 2021 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (...

2021-03-30 00:38 5128

HOYA Confirm the Long Term Technical Collaboration and Supply Agreement Related to Endoscopic Ultrasound Systems

TOKYO, March 29, 2021 /PRNewswire/ -- HOYA Corporation (TSE:7741, "HOYA") today confirms that the five year contract announced onJuly 6, 2020 for technical collaboration and supply of diagnostics ultrasound systems and ultrasound sensor with Hitachi, will become effective as ofMarch 31st of 2021....

2021-03-29 22:00 3423

Tigermed Reports 2020 Annual Results With Solid Growth

HANGZHOU, China, March 29, 2021 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (stock code: 300347.SZ / 3347.HK), a leading provider of innovative clinical research solutions for biopharmaceutical and medical device industry, reports its annual results for the year endedDecember 31, 2020 ...

2021-03-29 21:21 4664

Kazia Licenses Rights to Paxalisib in Greater China to Simcere, a Leading Chinese Pharmaceutical Company

SYDNEY, March 29, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd (Simcere) (HKSE: 2096) to develop and commercialise...

2021-03-29 17:43 5671

Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company's COVID-19 Vaccine Candidate

NEW BRUNSWICK, N.J., March 29, 2021 /PRNewswire/ -- Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vaccine Acquisition Task Team (AVATT) to make available up to 220 million dos...

2021-03-29 16:07 5966

HOYA Confirm the Long Term Technical Collaboration and Supply Agreement Related to Endoscopic Ultrasound Systems

TOKYO, March 29, 2021 /PRNewswire/ -- HOYA Corporation (TSE:7741, "HOYA") today confirms that the five year contract announced onJuly 6, 2020 for technical collaboration and supply of diagnostics ultrasound systems and ultrasound sensor with Hitachi, will become effective as ofMarch 31st of 2021....

2021-03-29 16:00 3290

Jacobio Pharma Announces CNY486 Million Revenue for 2020 Annual Results

BEIJING and BOSTON, March 29, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) announced its first annual results after itsHong Kong listing. By the end ofDecember 31, 2020, its annual revenue was 486 million yuan and R&D expenses exceeded230 million yuan and increased 66% compared to 2019....

2021-03-29 13:11 3825

Navigating China's Medical Technology, Regulations, Quality, and Future; Hundreds of Experts Gathered at On-site Conferences of Medtec China

SHANGHAI, March 29, 2021 /PRNewswire/ -- Medtec China 2021 will be held in Halls 2&4 of the Shanghai World Expo Exhibition Hall on September 1–3, and the "Innovation Technology Forum and Regulation Summit" will be held at the same time. This summit caters to the development trend and focus of Ch...

2021-03-29 09:30 3676

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint

SHANGHAI, March 29, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Phase 2 study of its innovative PD-1 inhibitor HLX10 in patients with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) solid tumors that fail t...

2021-03-29 08:27 4927

Making Most out of Launched Products Fueling Diversified Innovation through Integrated Platform

SHANGHAI, March 28, 2021 /PRNewswire/ -- Henlius (2696.HK) announced the financial results for the year ended31 December 2020. 2020 marked a meaningful year for Henlius as the Company gathered the pace in commercialization and continued the momentum for innovation. The Company delivered a total r...

2021-03-28 11:16 3667

Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS

TAIPEIMarch 27, 2021 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), today announced the initiation of patient dosing in the Phase 2/3 clinical trial of FP-025, its highly selective oral MMP-12 inhibitor, in adult patients with severe to critical COVID-19 with associated...

2021-03-28 11:04 2869

China Pharma Holdings, Inc. Reports Fiscal Year 2020 Financial Results

HAIKOU CITY, China, March 26, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI)  ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced financial results for the ...

2021-03-27 05:00 9936

Genscript Biotech Reports Full Year 2020 Financial Results

Highlights: * Revenue of the Group for the year ended December 31, 2020 was approximately US$390.8 million, representing an increase of 42.9% as compared with approximatelyUS$273.4 million for the year ended December 31, 2019 * Gross profit of the Group for the year ended December 31, 2...

2021-03-27 02:16 7338

Modern Chinese Medicine Announces Year 2020 Annual Results

Solid growth with focus to broaden the distribution network and raise R&D efforts PERFORMANCE HIGHLIGHTS * The Group posted a consolidated revenue of approximately RMB308.7 million for the year ended31 December 2020, representing an increase of approximately 41.1%. * For the year ended 31 D...

2021-03-26 22:08 12488

Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years

BAGSVÆRD, Denmark, March 26, 2021 /PRNewswire/ -- Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the treatment of obesity in adolescents aged 12–17 years...

2021-03-26 21:31 4027

Kintor Pharmaceutical Limited Announces 2020 Business Progress and Annual Results

SUZHOU, China, March 26, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (stock code 9939.HK, "Kintor Pharmaceutical" or the "Company"), a clinical-stage biotechnology company developing small molecule and biological therapeutics, recently announced its business highlights and financial result...

2021-03-26 20:54 6911
1 ... 614615616617618619620 ... 645